Drug · CHEMBL1237119
Comparisons in its trials33
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 33
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tyvaso vs Control: serious adverse events | 96 of 666 | 94 of 667 | 1,333 | NCT01266265 | Trial comparisons |
| Active vs Placebo Arm: Clinical Worsening Assessment | 8 of 174 | 12 of 176 | 350 | NCT00325442 | Trial comparisons |
| Active vs Placebo Arm: serious adverse events | 32 of 174 | 33 of 176 | 350 | NCT00325442 | Trial comparisons |
| Inhaled Treprostinil vs Placebo: Incidence of Clinical Worsening | 37 of 163 | 54 of 163 | 326 | NCT02630316 | Trial comparisons |
| Active Inhaled Treprostinil vs Placebo: deaths from any cause | 10 of 163 | 12 of 163 | 326 | NCT02630316 | Trial comparisons |
| Active Inhaled Treprostinil vs Placebo: serious adverse events | 38 of 163 | 42 of 163 | 326 | NCT02630316 | Trial comparisons |
| UT-15C SR vs Placebo: serious adverse events | 23 of 157 | 23 of 153 | 310 | NCT00887978 | Trial comparisons |
| LIQ861 Add-On vs Tyvaso Transition: deaths from any cause | 0 of 121 | 0 of 121 | 242 | NCT03399604 | Trial comparisons |
| LIQ861 Add-On vs Tyvaso Transition: serious adverse events | 15 of 121 | 6 of 121 | 242 | NCT03399604 | Trial comparisons |
| Inhaled Treprostinil vs Placebo: serious adverse events | 9 of 115 | 13 of 120 | 235 | NCT00147199 | Trial comparisons |
| UT-15C (Oral Treprostinil) vs Placebo: Clinical Worsening Assessment | 15 of 151 | 8 of 77 | 228 | NCT00325403 | Trial comparisons |
| UT-15C (Oral Treprostinil) vs Placebo: deaths from any cause | 9 of 151 | 6 of 77 | 228 | NCT00325403 | Trial comparisons |
| UT-15C (Oral Treprostinil) vs Placebo: serious adverse events | 27 of 151 | 15 of 77 | 228 | NCT00325403 | Trial comparisons |
| Oral Treprostinil vs Placebo: deaths from any cause | 0 of 41 | 1 of 43 | 84 | NCT03037580 | Trial comparisons |
| Oral Treprostinil vs Placebo: serious adverse events | 11 of 41 | 8 of 43 | 84 | NCT03037580 | Trial comparisons |
| Cohort A: Treprostinil vs Cohort B: Non-Treprostinil PAH Medications: deaths from any cause | 0 of 20 | 0 of 23 | 43 | NCT03888365 | Trial comparisons |
| Cohort A: Treprostinil vs Cohort B: Non-Treprostinil PAH Medications: serious adverse events | 0 of 20 | 0 of 23 | 43 | NCT03888365 | Trial comparisons |
| IV Remodulin vs Placebo: deaths from any cause | 4 of 20 | 2 of 21 | 41 | NCT02261883 | Trial comparisons |
| IV Remodulin vs Placebo: serious adverse events | 8 of 20 | 3 of 21 | 41 | NCT02261883 | Trial comparisons |
| Treprostinil vs Saline: deaths from any cause | 0 of 16 | 0 of 18 | 34 | NCT02498444 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1237119/comparisons